China Pioneer Pharma Holdings Limited
Simbols: 1345.HK
HKSE
1.42
HKDTirgus cena šodien
13.7445
P/E koeficients
0.0000
PEG koeficients
1.67B
MRK Cap
- 0.04%
DIV ienesīgums
China Pioneer Pharma Holdings Limited (1345-HK) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 124.4 | 289 | 402.1 | ||||||||||||
balance-sheet.row.short-term-investments | 0 | 10 | 75 | 177.2 | ||||||||||||
balance-sheet.row.net-receivables | 0 | 448.4 | 413.2 | 251.8 | ||||||||||||
balance-sheet.row.inventory | 0 | 417.9 | 321.1 | 294.9 | ||||||||||||
balance-sheet.row.other-current-assets | 0 | 126.2 | 186.6 | 241.5 | ||||||||||||
balance-sheet.row.total-current-assets | 0 | 1106.9 | 1134.9 | 1013.1 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 247.4 | 221.6 | 91.1 | ||||||||||||
balance-sheet.row.goodwill | 0 | 6.2 | 6.2 | 0 | ||||||||||||
balance-sheet.row.intangible-assets | 0 | 30.2 | 37 | 45.9 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 36.4 | 43.3 | 45.9 | ||||||||||||
balance-sheet.row.long-term-investments | 0 | 117.1 | 156.2 | 82.2 | ||||||||||||
balance-sheet.row.tax-assets | 0 | 2.3 | 8.6 | 12 | ||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 20.7 | -8.6 | -12 | ||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 424 | 421 | 219.2 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 15.8 | 96.1 | ||||||||||||
balance-sheet.row.total-assets | 0 | 1530.9 | 1571.7 | 1328.5 | ||||||||||||
balance-sheet.row.account-payables | 0 | 284.9 | 329.3 | 262 | ||||||||||||
balance-sheet.row.short-term-debt | 0 | 61.3 | 29.6 | 14 | ||||||||||||
balance-sheet.row.tax-payables | 0 | 17.8 | 39.8 | 24.9 | ||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 12.7 | 8 | 0.1 | ||||||||||||
Deferred Revenue Non Current | 0 | 41.4 | 43.6 | 43.6 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 0 | 0 | 143.5 | 86.2 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 70.4 | 76.3 | 69.3 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 14 | 8.7 | 0.2 | ||||||||||||
balance-sheet.row.total-liab | 0 | 513.1 | 549.2 | 417.5 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 84.1 | 59 | ||||||||||||
balance-sheet.row.common-stock | 0 | 77.4 | 77.4 | 77.6 | ||||||||||||
balance-sheet.row.retained-earnings | 0 | 634.9 | 594.8 | 444.2 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 929 | -84.1 | -59 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | -634.9 | 335.6 | 386.2 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 1006.4 | 1007.8 | 908 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 1530.9 | 1571.7 | 1328.5 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 11.3 | 14.7 | 3 | ||||||||||||
balance-sheet.row.total-equity | 0 | 1017.8 | 1022.5 | 911 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||
Total Investments | 0 | 117.1 | 231.2 | 259.4 | ||||||||||||
balance-sheet.row.total-debt | 0 | 74 | 37.6 | 14.1 | ||||||||||||
balance-sheet.row.net-debt | 0 | -40.4 | -176.4 | -210.8 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 235.3 | 142.6 | 52.4 | |||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 13.6 | 12.9 | 8.4 | |||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.change-in-working-capital | 0 | -193.5 | 226.3 | -147.3 | |||||||||||||
cash-flows.row.account-receivables | 0 | -168 | 66.2 | -65.3 | |||||||||||||
cash-flows.row.inventory | 0 | -25.5 | 160.2 | -82.1 | |||||||||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.other-non-cash-items | 0 | 37.9 | -139.8 | 160.8 | |||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -74.3 | -16.6 | -34.9 | |||||||||||||
cash-flows.row.acquisitions-net | 0 | -26.7 | -2.4 | -20.9 | |||||||||||||
cash-flows.row.purchases-of-investments | 0 | -717.2 | -2020.3 | -512.9 | |||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 798.1 | 1976.4 | 570.5 | |||||||||||||
cash-flows.row.other-investing-activites | 0 | 7 | 71.4 | 22.1 | |||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -13 | 8.4 | 23.9 | |||||||||||||
cash-flows.row.debt-repayment | 0 | -1.1 | 0 | -0.1 | |||||||||||||
cash-flows.row.common-stock-issued | 0 | 26.9 | 10.4 | -2.8 | |||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -25.8 | -10.3 | -2.8 | |||||||||||||
cash-flows.row.dividends-paid | 0 | -84.7 | -129.9 | -111.9 | |||||||||||||
cash-flows.row.other-financing-activites | 0 | -6.4 | -10.4 | -135.5 | |||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -91 | -140.3 | -253 | |||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -0.1 | -0.3 | -0.4 | |||||||||||||
cash-flows.row.net-change-in-cash | 0 | -10.8 | 109.8 | -155.3 | |||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 214 | 224.9 | 115 | |||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 224.9 | 115 | 270.3 | |||||||||||||
cash-flows.row.operating-cash-flow | 0 | 93.3 | 242.1 | 74.2 | |||||||||||||
cash-flows.row.capital-expenditure | 0 | -74.3 | -16.6 | -34.9 | |||||||||||||
cash-flows.row.free-cash-flow | 0 | 19 | 225.4 | 39.4 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1566.7 | 1556 | 1434.8 | ||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 898.4 | 775.6 | 662.8 | ||||||||||||||
income-statement-row.row.gross-profit | 0 | 668.2 | 780.5 | 772 | ||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||
income-statement-row.row.other-expenses | 0 | 1.6 | 4.8 | 2.7 | ||||||||||||||
income-statement-row.row.operating-expenses | 0 | 488 | 496.6 | 574.6 | ||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 1386.5 | 1272.1 | 1237.4 | ||||||||||||||
income-statement-row.row.interest-income | 0 | 0.6 | 10.6 | 4 | ||||||||||||||
income-statement-row.row.interest-expense | 0 | 2.5 | 1.7 | 0.9 | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 46.9 | 62.3 | 14.2 | ||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 1.6 | 4.8 | 2.7 | ||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 46.9 | 62.3 | 14.2 | ||||||||||||||
income-statement-row.row.interest-expense | 0 | 2.5 | 1.7 | 0.9 | ||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 18.9 | 13.2 | 12.7 | ||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||
income-statement-row.row.operating-income | 0 | 133.5 | 232.2 | 187.2 | ||||||||||||||
income-statement-row.row.income-before-tax | 0 | 180.4 | 294.5 | 201.4 | ||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 51.5 | 64.5 | 60.6 | ||||||||||||||
income-statement-row.row.net-income | 0 | 145.7 | 235.3 | 142.6 |
Biežāk uzdotie jautājumi
Kas ir China Pioneer Pharma Holdings Limited (1345.HK) kopējie aktīvi?
China Pioneer Pharma Holdings Limited (1345.HK) kopējie aktīvi ir 1530905000.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir N/A.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.427.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir -0.127.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 0.093.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir 0.085.
Kāda ir China Pioneer Pharma Holdings Limited (1345.HK) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir 145718000.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 74020000.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 488030000.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 0.000.